

## European Journal of Pharmacology

The EUROPEAN JOURNAL OF PHARMACOLOGY publishes full-length papers, short communications and rapid communications on the mechanisms of action of chemical substances affecting biological systems. The journal also considers short reviews (not exceeding 12 pages in print) intended to debate recent advances in rapidly developing fields that are within its scope.

Full length papers and short communications are grouped under the following headings: Pharmacogenomics, Molecular and cellular pharmacology, Neuropharmacology and analgesia, Behavioural pharmacology, Cardiovascular pharmacology, Pulmonary, gastrointestinal and urogenital pharmacology, Immunopharmacology and inflammation, and Endocrine pharmacology.

Manuscripts submitted to the journal are accepted on the understanding that: (1) they are subject to editorial review, (2) they have not been and will not be published in whole or in part in any other journal and (3) the recommendations from the declaration of Helsinki and Tokyo, for humans, and the European Community guidelines as accepted principles for the use of experimental animals have been adhered to. The European Journal of Pharmacology will, therefore, only consider manuscripts that describe experiments which have been carried out under approval of an institutional or local ethics committee. Authors must state in the manuscript that protocol complies with the particular recommendation and that approval of their protocols was obtained.

A Guide for Authors is published at the end of each issue.

Founded in 1967. Founding editors: David de Wied and Jacques van Rossum.

**Editors:** W.H. GISPEN, Utrecht (chairman) F.P. NIJKAMP, Utrecht

**Assistant editor:** F. ENGELS, Utrecht

**Founding editor:** D. DE WIED

### Editorial board:

I.M. ADCOCK, London  
C. ADVENIER, Paris  
J.M. BAEYENS, Granada  
L. BARTHÓ, Pécs  
A. BESPALOV, Saint-Petersburg  
G. BIGGIO, Cagliari  
S.D. BRAIN, London  
O.E. BRODDE, Halle  
H. BULT, Wilrijk  
D.B. BYLUND, Omaha  
F. CATTABENI, Milan  
C.H. CHO, Hong Kong  
O. CIVELLI, Irvine

R. DANTZER, Bordeaux  
F. DRAGO, Catania  
M. ENDOH, Yamagata  
E. FRIDE, Ariel  
G.F. GEBHART, Iowa City  
M. HAMON, Paris  
M. LAZDUNSKI, Valbonne  
R. LEFEBVRE, Gent  
M.J. LOHSE, Würzburg  
W. LÖSCHER, Hannover  
J. McCULLOCH, Edinburgh  
K.P. MINNEMAN, Atlanta  
S. NAHORSKI, Leicester

D.W. NEBERT, Cincinnati  
J.M. PFEILSCHIFTER, Frankfurt  
J.P. PIN, Montpellier  
R. PRZEWLOCKI, Kraków  
P.R. SAXENA, Rotterdam  
A. SCHOUSBOE, Copenhagen  
P. SKOLNICK, Hackensack  
J.C. STOCLET, Strasbourg  
E.S. VIZI, Budapest  
S.P. WELCH, Richmond  
B.J.R. WHITTLE, London  
Z. WIESENFELD-HALLIN, Huddinge  
J. WIKBERG, Uppsala

### Consultants:

E. AIZENMAN, Pittsburgh; K.-E. ANDERSSON, Lund; E. BEUBLER, Graz; J. BOCKAERT, Montpellier; S.J. COOPER, Liverpool; R. COUTURE, Montreal; G. DI CHIARA, Cagliari; G.Z. FEUERSTEIN, West Point; A.W. FORD-HUTCHINSON, West Point; J.A. GARCÍA-SÁINZ, Mexico City; A.R. GREEN, London; A. HERMAN, Antwerpen; P. HOLZER, Graz; D. HOYER, Basel; J.P. HUIDOBRO-TORO, Santiago; E.C. HULME, London; K.H. JAKOBS, Essen; H. KARAKI, Tokyo; H. KLEINERT, Mainz; K.P. LESCH, Würzburg; B.R. LUCCHESI, Ann Arbor; H. MEURS, Groningen; M.J. MILLAN, Croissy-sur-Seine; F. MORONI, Florence; T. NABESHIMA, Nagoya; M. OTSUKA, Tokyo; J.N. PENNEFATHER, Parkville; A. PERTOVAARA, Turku; R. QUIRION, Verdun; U. RAVENS, Essen; M.E.A. REITH, Chicago; H. SCHOEMAKER, Bagneux; J.F.M. SMITS, Maastricht; K. STARKE, Freiburg im Breisgau; L.A. URBAN, Basel; R.J. WINQUIST, Cambridge, MA



ELSEVIER

European Journal of Pharmacology 327 (1997) 195–207

ejp

## Tolterodine – a new bladder-selective antimuscarinic agent

Lisbeth Nilvebrant <sup>a,\*</sup>, Karl-Erik Andersson <sup>b</sup>, Per-Göran Gillberg <sup>c</sup>, Matthias Stahl <sup>b</sup>,  
Bengt Sparf <sup>c</sup>

<sup>a</sup> Medical Department Urology, Pharmacia & Upjohn AB, S-752 81, Uppsala, Sweden

<sup>b</sup> Department of Clinical Pharmacology, University Hospital, Lund, Sweden

<sup>c</sup> Department of Pharmacology, Pharmacia & Upjohn AB, Uppsala, Sweden

Received 17 October 1996; revised 13 March 1997; accepted 18 March 1997

### Abstract

Tolterodine is a new muscarinic receptor antagonist intended for the treatment of urinary urge incontinence and other symptoms related to an overactive bladder. The aim of the present study was to compare the antimuscarinic properties of tolterodine with those of oxybutynin, *in vitro* and *in vivo*. Tolterodine effectively inhibited carbachol-induced contractions of isolated strips of urinary bladder from guinea pigs ( $K_B$  3.0 nM;  $pA_2$  8.6; Schild slope 0.97) and humans ( $K_B$  4.0 nM;  $pA_2$  8.4; Schild slope 1.04) in a concentration-dependent, competitive manner. The affinity of tolterodine was similar to that derived for oxybutynin ( $K_B$  4.4 nM;  $pA_2$  8.5; Schild slope 0.89) in the guinea-pig bladder. Tolterodine (21–2103 nmol/kg (0.01–1 mg/kg); intravenous infusion) was significantly more potent in inhibiting acetylcholine-induced urinary bladder contraction than electrically-induced salivation in the anaesthetised cat. In contrast, oxybutynin displayed the opposite tissue selectivity. Radioligand binding data showed that tolterodine bound with high affinity to muscarinic receptors in urinary bladder ( $K_i$  2.7 nM), heart ( $K_i$  1.6 nM), cerebral cortex ( $K_i$  0.75 nM) and parotid gland ( $K_i$  4.8 nM) from guinea pigs and in urinary bladder from humans ( $K_i$  3.3 nM). Tolterodine and oxybutynin were equipotent, except in the parotid gland, where oxybutynin bound with 8-times higher affinity ( $K_i$  0.62 nM). Binding data on human muscarinic m1–m5 receptors expressed in Chinese hamster ovary cells showed that oxybutynin, in contrast to tolterodine, exhibits selectivity (10-fold) for muscarinic m3 over m2 receptors. The  $K_B$  value determined for oxybutynin (4.4 nM) in functional studies on guinea-pig bladder correlated better with the binding affinity at muscarinic  $M_2/m_2$  receptors ( $K_i$  2.8 and 6.7 nM) than at muscarinic  $M_3/m_3$  receptors ( $K_i$  0.62 and 0.67 nM). The tissue selectivity demonstrated for tolterodine *in vivo* cannot be attributed to selectivity for a single muscarinic receptor subtype. However, the combined *in vitro* and *in vivo* data on tolterodine and oxybutynin may indicate either that muscarinic  $M_3/m_3$  receptors in glands are more sensitive to blockade than those in bladder smooth muscle, or that muscarinic  $M_2/m_2$  receptors contribute to bladder contraction.

**Keywords:** Urinary bladder contraction; Salivation; Muscarinic receptor subtype; Muscarinic receptor antagonist; (Guinea pig); (Cat); (Human)

### 1. Introduction

Tolterodine (Fig. 1) is a new muscarinic receptor antagonist intended for the treatment of urinary urge incontinence and other symptoms of an overactive bladder. The pharmacological treatment of urge incontinence has for a long time been based on muscarinic receptor antagonists, e.g., propantheline, emepronium and oxybutynin (Andersson, 1988; Wein et al., 1994), and it is generally agreed that contractions of the human urinary bladder are mediated mainly through stimulation of acetylcholine mus-

carinic receptors (Andersson, 1993). Oxybutynin is currently considered to be the drug of choice in the treatment of bladder overactivity (Yarker et al., 1995). The effectiveness of oxybutynin has been demonstrated in several controlled clinical studies, but the incidence of classical antimuscarinic side effects often leads to discontinuation of treatment. Dryness of the mouth is the most prevalent side effect, experienced by at least 50% of patients on oxybutynin therapy (Yarker et al., 1995).

The existence of molecularly distinct muscarinic receptor subtypes has been well established (Hulme et al., 1990; Caulfield, 1993). Thus, five genes encoding for muscarinic receptors (m1–m5) have been cloned and expressed in cell lines, while three muscarinic receptor subtypes ( $M_1$ – $M_3$ )

\* Corresponding author. Tel.: (46-18) 16-4420; Fax: (46-18) 16-6464.




Fig. 1. Chemical structure of tolterodine.

can be distinguished by pharmacological means. A fourth pharmacological subtype ( $M_4$ ) has also been defined, although muscarinic  $M_4$ -selective antagonists are not yet available. Roughly, muscarinic  $M_1$  receptors prevail in neuronal tissues while the heart appears to contain a homogenous population of muscarinic  $M_2$  receptors and exocrine glands are considered to contain mainly muscarinic  $M_3$  receptors. The muscarinic  $M_4$  receptors are found in striatum, cortex and peripheral rabbit lung. However, it is commonly found that more than one receptor subtype coexist within a tissue or cell (Hulme et al., 1990; Caulfield, 1993).

Many smooth muscles contain both muscarinic  $M_2$  ('cardiac') and muscarinic  $M_3$  ('glandular') receptors (for review, see Eglen et al., 1994). The presence of mRNA for muscarinic  $m_2$  and  $m_3$  receptors has been demonstrated in the urinary bladder of rat, pig (Maeda et al., 1988) and humans (Yamaguchi et al., 1994). Radioligand binding data indicate the presence of muscarinic  $M_2$  and  $M_3$ , as well as muscarinic  $M_1$ , receptors in human bladder tissue and that muscarinic  $M_3$  receptors may predominate (Kondo et al., 1995; Wammack et al., 1995). On the other hand, immunoprecipitation data indicate that the proportion of muscarinic  $m_2$  and  $m_3$  receptors is 3:1 in the bladders from humans, guinea pigs and rabbits, and 9:1 in the rat bladder (Wang et al., 1995). Radioligand binding data on selective antagonists in the guinea-pig bladder (Nilvebrant and Sparf, 1986, 1988) and other smooth muscles (Giraldo et al., 1987; Michel and Whiting, 1988; Eglen et al., 1994) most often reflect the pharmacology of the muscarinic  $M_2$  receptors. This probably reflects a predominance of muscarinic  $M_2/m_2$  receptors in smooth muscles and the rather limited subtype selectivity of available antagonists. However, functional *in vitro* data on a number of selective antagonists indicate that the contraction of most smooth muscles, including the urinary bladder, is mediated by muscarinic  $M_3$  receptors (Caulfield, 1993; Eglen et al., 1994; Tobin and Sjögren, 1995; Wang et al., 1995). The functional role of muscarinic  $M_2$  receptors is still mysterious, but emerging evidence suggests that the importance of the muscarinic  $M_2/m_2$  receptors in various smooth muscles might have been underestimated (Zhang and Buxton, 1991; Griffin and Ehlert, 1992; Caulfield, 1993; Thomas et al., 1993; Eglen et al., 1994; Chen et al., 1995; Reddy et al., 1995).

The aim of the present study was to compare the antimuscarinic properties of tolterodine and oxybutynin. Oxybutynin has been characterised as a muscarinic  $M_1/M_3$ -selective antagonist (Nilvebrant and Sparf, 1982, 1983b, 1986; Lazareno et al., 1990; Noronha-Blob and Kachur, 1991). For purposes of comparison, the classical non-selective muscarinic receptor antagonist atropine was also included. The inhibitory effects of tolterodine, oxybutynin and atropine on urinary bladder contraction and salivary secretion *in vivo* were studied in the anaesthetised cat. The *in vitro* studies comprised radioligand binding and functional studies on bladders from guinea pigs and humans. Radioligand binding studies were also carried out on parotid gland, heart and cerebral cortex from guinea pigs, as well as on human muscarinic  $m_1$ – $m_5$  receptors expressed in Chinese hamster ovary (CHO) cells.

## 2. Materials and methods

### 2.1. *In vitro* studies

#### 2.1.1. Guinea-pig tissues

Male guinea pigs (Dunkin Hartley, weighing 300–500 g) were killed by a blow on the neck and exsanguinated. The cerebral cortex was dissected on ice and the other tissues in Krebs-Henseleit solution, as previously described (Nilvebrant and Sparf, 1982, 1983a, 1986). Urinary bladders for functional *in vitro* studies were cut into strip preparations (3 × 3 × 12 mm). Tissues for radioligand binding studies were homogenised, as described below.

#### 2.1.2. Human urinary bladder

Detrusor specimens from the dome of the bladder were obtained from 23 patients (mean age 63 ± 2 years; range 44–75 years) undergoing surgery for bladder malignancy. Some of the patients had received preoperative radiation therapy (20 Gy). However, the muscarinic receptor density in the human bladder and the affinity for muscarinic receptor antagonists does not appear to be influenced by age, sex and radiotherapy (Nilvebrant et al., 1985). All specimens were taken from a macroscopically normal part of the detrusor. No mucosal tissue was included. For functional *in vitro* studies, dissected bladder specimens were cut into strip preparations (1 × 1 × 8 mm; 6–12 strips were obtained from each patient). Tissue for radioligand binding studies was frozen at –70°C and stored at this temperature until used in the assays.

#### 2.1.3. Chinese hamster ovary (CHO) cells

CHO cell lines transfected with genes encoding the human muscarinic receptor subtypes  $m_1$ ,  $m_2$ ,  $m_3$  and  $m_4$ , respectively, were obtained from Dr T. Bonner, National Institutes of Health, USA, while cells expressing the  $m_5$  subtype were obtained from Dr M. Brann, University of Vermont, USA (Buckley et al., 1989). The cells were

cultured in a medium consisting of equal parts of Dulbecco's modified Eagle's medium (DMEM) and HAM's F12, respectively. The medium was supplemented with foetal bovine serum (10%), L-glutamine (4 mM) and penicillin/streptomycin (100 U/ml), at 37°C in a humidified atmosphere (7% CO<sub>2</sub>, 93% air) in tissue culture flasks or roller bottles. Cultures were continuously harvested every second or third day and stored at -70°C until used in radioligand binding studies.

#### 2.1.4. Functional *in vitro* studies

Guinea-pig and human bladder strips were transferred to jacketed tissue baths (5 ml) and mounted between two hooks. One of the hooks was connected to a force transducer (FT 03, Grass Instruments). The baths contained a temperature-controlled (37°C) Krebs-Henseleit solution, which was continuously aerated with carbogen (93.5% or 95% O<sub>2</sub>/6.5% or 5% CO<sub>2</sub>) to maintain pH at 7.4. Isometric tension was recorded by a Polygraph (Grass, model 79 D). A resting tension of 5 mN was initially applied to each preparation. During stabilisation (45–60 min) the strips were repeatedly washed and the resting tension was adjusted. The Krebs-Henseleit solution used for guinea-pig bladder contained (mM): NaCl (119), KCl (4.6), CaCl<sub>2</sub> (1.5), MgCl<sub>2</sub> (1.2), NaHCO<sub>3</sub> (20), NaH<sub>2</sub>PO<sub>4</sub> (1.4) and glucose (11). The Krebs-Henseleit buffer used for human preparations had a slightly different composition (mM): NaCl (118), KCl (4.6), CaCl<sub>2</sub> (1.5), MgSO<sub>4</sub> (1.2), NaHCO<sub>3</sub> (24.9), KH<sub>2</sub>PO<sub>4</sub> (1.4) and glucose (11). When responses of human strips to K<sup>+</sup> were studied, the NaCl in the Krebs solution was replaced by KCl to give a K<sup>+</sup> concentration of 124 mM.

Guinea-pig preparations were exposed to a standard concentration of the muscarinic receptor agonist carbachol (3 μM; EC<sub>80</sub>) to establish reproducible responses (three subsequent contractions with ≤ 10% variation in amplitude) before a concentration–response curve to carbachol (control) was generated using cumulative addition. After exposure of the bladder strips to a fixed concentration of antagonist for 60 min (Nilvebrant, 1986), the concentration–response curve to carbachol was repeated in the presence of antagonist. Responses were expressed as a percentage of the maximal contractile response elicited by carbachol in the control curve.

The viability of human bladder preparations was controlled by exposure to K<sup>+</sup> (124 mM) before cumulative concentration–response curves to carbachol were established (control). Two consecutive control curves were generated before incubation with tolterodine, but all responses were expressed as a percentage of the maximal contractile response in the control curve immediately preceding incubation with tolterodine. The strips were exposed to tolterodine for 20 min before the concentration–response curve to carbachol was repeated.

When human bladder strips were stimulated electrically, two electrodes were placed on each side of the preparation

and parallel to it. Stimulation was delivered by a Grass S88 electrical stimulator as single square-wave pulses with a duration of 0.8 ms. The voltage was supramaximal and the stimulation was given in 5 s trains with an interval of 2 min. The frequency interval used was 1–45 Hz. The frequency–response relations were established for each strip, and a frequency producing 70–80% of maximum response was selected. The strips were stimulated at this frequency at 2-min intervals, and tolterodine was then added cumulatively.

EC<sub>50</sub> values for carbachol were determined in the absence and presence of antagonist, respectively. The affinity of the antagonist was calculated as the dissociation constant  $K_B$  (Schild, 1949). The mean ± S.E.M. of the  $K_B$  values determined using different antagonist concentrations in (*n*) preparations was calculated. The IC<sub>50</sub> value for tolterodine in electrically stimulated preparations was calculated by linear interpolation.

#### 2.1.5. Membrane preparations for radioligand binding studies

All preparation steps were carried out on ice. Human bladder specimens obtained from different patients were never pooled. Thawed human bladder samples, dissected guinea-pig bladders, parotid glands and hearts were homogenised in ten volumes of ice-cold sodium-potassium phosphate buffer (50 mM; pH 7.4) containing 1 mM phenylmethylsulphonyl fluoride, using a Polytron PT-3000 (guinea-pig urinary bladder and parotid gland: 26 000 rpm, 2 × 15 s; guinea-pig heart: 1300 rpm, 2 × 15 s; human urinary bladder: 26 000 rpm, 3 × 15 s; with a 30 s cooling interval between bursts). Guinea-pig cerebral cortex was homogenised using a Potter-Elvehjem Teflon/glass homogeniser. Before use in the assays, tissue homogenates were diluted with ice-cold phosphate/phenylmethylsulphonyl fluoride buffer to a final protein concentration of ≤ 0.3 mg/ml. Homogenates of CHO cells containing muscarinic m1–m5 receptors were prepared in 1–2 ml of ice-cold sodium phosphate buffer (25 mM, pH 7.4) containing 5 mM MgCl<sub>2</sub> (Buckley et al., 1989) and 1 mM phenylmethylsulphonyl fluoride, using a glass-glass homogeniser. The cell homogenates were diluted with ice-cold phosphate/phenylmethylsulphonyl fluoride buffer to 1000–10 000 times the original wet weight (protein concentrations of 4–190 μg/ml) before use in the assays. Protein concentration in the final tissue homogenates and in cell homogenates containing > 25 μg/ml were determined by the method of Lowry et al. (1951). The BioRad Protein Assay (Bradford, 1976) was used for cell homogenates with protein concentrations below 25 μg/ml. Bovine serum albumin was used as standard for both methods.

#### 2.1.6. Radioligand binding assays

The affinities of the unlabelled drugs were determined by competition experiments, using [<sup>3</sup>H](-)-1-quinuc-

lidinyl benzilate as tracer. Non-specific binding was determined in the presence of 10  $\mu$ M atropine. Total and non-specific binding of [ $^3$ H](–)-1-quinuclidinyl benzilate was determined in six samples each, while samples containing unlabelled antagonist were run in triplicate.

Tissue homogenates (1.0 ml) were incubated with [ $^3$ H](–)-1-quinuclidinyl benzilate (2 nM) and different concentrations of unlabelled antagonist under conditions of equilibrium: guinea-pig urinary bladder, 25°C for 60 min (Nilvebrant and Sparf, 1983a); parotid gland, 25°C for 210 min (Nilvebrant and Sparf, 1982); heart and cerebral cortex, 25°C for 80 min (Nilvebrant and Sparf, 1986); and human bladder, 25°C for 180 min (Nilvebrant et al., 1985). Incubations were terminated by centrifugation (Nilvebrant and Sparf, 1983a). The pellets were washed and the tubes allowed to dry before the tips containing the pellets were cut off and transferred to scintillation vials. Soluene-100 (Packard) was added (200  $\mu$ l/tube) and the samples were left overnight for solubilisation of the pellet. A scintillation cocktail (Instafluor or Ultima Gold, Packard) was added and radioactivity determined by liquid scintillation spectrometry (Packard TriCarb model 2200 CA or 2500 TR). A quench correction curve was used for the conversion of cpm to dpm.

Binding studies on CHO cell lines containing human muscarinic m1–m5 receptors were run in 24-well cultures plates. Cell homogenates (1.0 ml) were incubated with [ $^3$ H](–)-1-quinuclidinyl benzilate (1 nM) and different concentrations of unlabelled drug under conditions of equilibrium (37°C for 300 min). The optimal protein concentrations and the time required to reach equilibrium for each cell line was determined in a separate series of experiments (data not shown). Incubations were terminated by filtration through a cell harvester (Packard) onto GF/C filters (Packard). The filter plates were dried, 200  $\mu$ l of Microscint (Packard) added and the radioactivity was determined in a Packard Top Count scintillation counter (efficiency of 44–46%).

Data are presented as mean  $\pm$  S.E.M. of (*n*) experiments. In the competition binding experiments, IC<sub>50</sub> values for the antagonists were determined from the experimental concentration–inhibition curves. Dissociation constants ( $K_i$ ) were calculated by correcting the IC<sub>50</sub> values for the radioligand-induced parallel shift and the differences in receptor concentration, using the method described by Jacobs et al. (1975); see also Nilvebrant and Sparf (1982, 1983b) for details.

In order to verify that the density of muscarinic receptors in the human bladder and the affinity ( $K_d$ ) for [ $^3$ H](–)-1-quinuclidinyl benzilate were within the ranges previously reported (Nilvebrant et al., 1985), saturation experiments were performed in specimens from six individuals. Samples containing different concentrations of [ $^3$ H](–)-1-quinuclidinyl benzilate (0.05–5 nM) were incubated under conditions of equilibrium (25°C for 180 min), using atropine for determination of non-specific binding.

Receptor density and  $K_d$  were determined by Scatchard analysis of the saturation data. These parameters (receptor density  $122 \pm 9$  fmol/mg protein (range 93–146);  $K_d$   $0.12 \pm 0.02$  nM) were within the range of those previously determined in a series of 14 patients (receptor density  $164 \pm 15$  fmol/mg protein (range 77–231);  $K_d$   $0.14 \pm 0.02$  nM) (Nilvebrant et al., 1985).

## 2.2. *In vivo* studies

### 2.2.1. *Animals and anaesthesia*

Twenty-five female European short-haired cats (2.2–3.4 kg; 6–10 months old) were used. The animals were deprived of food overnight before the experiment. They were initially anaesthetised with an intraperitoneal injection of pentobarbital sodium (30–39 mg/kg), followed by intravenous (i.v.) administration of  $\alpha$ -chloralose (25 mg/ml in 5% sodium tetraborate; 25 mg/kg).

The animal was placed on an electrically heated pad and the body temperature was controlled by a feedback loop from a thermometer in the anus. Additional doses of  $\alpha$ -chloralose were given (176–312  $\mu$ l/kg per h) when required to maintain anaesthesia. In order to maintain homeostasis, a Ringer solution was administered (2.2–7.8 ml/kg per h).

### 2.2.2. *Surgery*

The animal was tracheotomised and a glass respiratory cannula was inserted and connected to a volumetric low-pressure transducer (Grass PT5A) for recording of respiratory volume. Both femoral arteries were catheterised with polyethylene tubing (PE90). One of these was connected to a blood pressure transducer (Statham P23DC). The other was used for intra-arterial (i.a.) administration of acetylcholine and collection of blood samples for determination of haematocrit and blood gases. The right femoral vein was catheterised (PE90) and connected to a 3-way stopcock for i.v. infusion of test compounds and Ringer solution.

The hypogastric and pelvic nerves were identified and transected. The ureters were cut and catheterised (PE10). A catheter (PE240) inserted into the urinary bladder through an incision in the proximal urethra. At the beginning of the experiment, this catheter was connected to an open vessel filled with temperature-controlled (37°C) saline that was placed approximately 15 cm above the animal. During stabilisation (about 1 h), the bladder relaxed and gradually became filled with saline under constant hydrostatic pressure. The bladder catheter was later connected to a pressure transducer (Statham p23A) for recording of intravesical pressure. The duct of the submandibular gland was exposed in the neck and catheterised (PE10). The parasympathetic chorda-lingual nerve was exposed and cut as proximally as possible. The peripheral nerve stump was placed on a bipolar electrode. Intravesical pressure, blood pressure, heart rate (derived from the blood pressure sig-

nal) and respiration rate were recorded on a Polygraph (Grass model 7D). Blood pressure, heart rate, respiration, blood gases and haematocrit were measured in order to monitor the general condition of the animal during the course of the experiment.

### 2.2.3. Experimental procedure

The cats were divided into four groups receiving tolterodine ( $n = 5$ ), oxybutynin ( $n = 5$ ), atropine ( $n = 5$ ), or saline ( $n = 10$ ; control group), respectively. Tolterodine (21–2103 nmol/kg (0.01–1 mg/kg)), oxybutynin (25–2538 nmol/kg (0.01–1 mg/kg)), atropine (0.86–86 nmol/kg (0.0003–0.03 mg/kg)) or saline were administered by i.v. infusion at a rate of 1 ml/kg per min. The animals were left to recover for at least 24 min between doses. Urinary bladder contractions were evoked by i.a. injection of a standard (submaximal) dose of acetylcholine (1–4  $\mu\text{g/kg}$ ), which produced a short-lasting (< 1 min), large (> 9 cmH<sub>2</sub>O) and reproducible (< 15% variation) increase in intravesical pressure. This standard dose was selected from a dose-response curve to acetylcholine (0.5–8  $\mu\text{g/kg}$ ) generated at the beginning of each experiment. Acetylcholine was administered before and approximately 9 and 16 min after each dose of antagonist. Salivation was induced by supramaximal electrical stimulation (6 V, 2 ms, 5 Hz) of the chorda-lingual nerve. The frequency-response relationship was established at the beginning of each experiment using frequencies of 0.5, 1, 2 and 5 Hz over 2 min. The frequency used in the experiments (5 Hz) produced a mean salivary secretion of  $372 \pm 24 \mu\text{l}$  during 2 min. Electrical stimulation of the chorda-lingual nerve was performed before and approximately 7 min after each dose of antagonist. Arterial blood samples for determination of haematocrit and blood gases were drawn before the administration of each dose of test compound.

### 2.3. Calculations and statistics

Effects of drugs on urinary bladder contractions and salivary secretion are expressed as percentage inhibition of the control responses. Data are presented as mean  $\pm$  S.E.M. of ( $n$ ) animals. Differences between the inhibitory effect exerted by the antagonist on urinary bladder contractions and salivary secretion were analysed for each dose level using a paired Student's *t*-test. Differences between the doses of antagonist causing a 50% inhibition of these responses ( $\text{IC}_{50}$ ) were also analysed. *P* values < 0.05 were considered significant.

### 2.4. Drugs and chemicals

The following drugs and chemicals were used: tolterodine tartrate [(*R*)-*N,N*-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropanamine hydrogen L-(+)-tartrate], saline and Ringer solution (Pharmacia & Upjohn, Sweden); carbamylcholine chloride (carbachol), acetylcholine chlo-

ride, phenylmethylsulphonyl fluoride, oxybutynin hydrochloride and atropine sulphate (Sigma, USA); [<sup>3</sup>H](–)-1-quinuclidinyl benzilate, 32–52 Ci/mmol (equivalent to 1.18–1.94 TBq/mmol) (Amersham, UK or Du Pont NEN, USA); pentobarbital sodium (Apoteksbolaget, Sweden);  $\alpha$ -chloralose (Merck, Germany); sodium borate (Mallinkrodt, USA); DMEM and HAM's F12 (National Veterinary Institute, Sweden); foetal bovine serum albumin (HyClone Lab, USA); L-glutamine and penicillin/streptomycin (ICN Biomedicals, USA). Other chemicals used (analytical grade) were purchased from general commercial sources.

The radioligand [<sup>3</sup>H](–)-1-quinuclidinyl benzilate was diluted in absolute ethanol. Stock solutions of tolterodine, oxybutynin, atropine and carbachol for functional in vitro studies were prepared and diluted in redistilled water. Stock solutions of tolterodine, oxybutynin, atropine and acetylcholine for in vivo studies were prepared and diluted in saline. Fresh solutions were prepared for each experiment.

## 3. Results

### 3.1. In vitro studies

#### 3.1.1. Functional studies on isolated urinary bladder

Tolterodine effectively inhibited carbachol-induced contractions of guinea-pig isolated urinary bladder strips in a concentration-dependent manner (Fig. 2). The Schild plot (not shown) was linear (slope 0.97;  $\text{pA}_2$  8.6), indicating a simple competitive blockade of the bladder muscarinic receptors. Similar data were obtained for oxybutynin (Schild slope 0.89;  $\text{pA}_2$  8.5). Tolterodine was thus equipotent to oxybutynin, but less potent than atropine (Table 1).




Fig. 2. Effect of tolterodine on the concentration-response curve to carbachol in guinea-pig isolated urinary bladder. The contractile responses elicited by increasing concentrations of carbachol (cumulative additions) were recorded in the absence (control) and presence, respectively, of tolterodine at concentrations of 10 nM ( $\blacktriangledown$ ), 30 nM ( $\blacklozenge$ ) and 500 nM ( $\blacktriangle$ ). The time of incubation with tolterodine was 60 min. Control data ( $\bullet$ ) represent the mean ( $\pm$  S.E.M.) of 14 individual experiments. The  $\text{EC}_{50}$  value for carbachol was  $2.4 \pm 0.3 \mu\text{M}$ .

Table 1  
Affinities, expressed as the dissociation constants ( $K_i$ ), for muscarinic receptors in guinea-pig cerebral cortex, heart and parotid gland

Compound	Urinary bladder			Cerebral cortex		Heart		Parotid gland	
	$K_B$ (nM)	$K_i$ (nM)	$n_H$	$K_i$ (nM)	$n_H$	$K_i$ (nM)	$n_H$	$K_i$ (nM)	$n_H$
Tolterodine	$3.0 \pm 0.2$ (15)	$2.7 \pm 0.2$ (6)	$1.02 \pm 0.03$ (6)	$0.75 \pm 0.01$ (5)	$1.05 \pm 0.03$ (5)	$1.6 \pm 0.04$ (5)	$1.04 \pm 0.06$ (5)	$4.8 \pm 0.3$ (5)	$1.04 \pm 0.03$ (5)
Oxybutynin	$4.4 \pm 0.6$ (14)	$4.0 \pm 0.4$ (6)	$0.99 \pm 0.01$ (6)	$0.41 \pm 0.05$ (5)	$0.97 \pm 0.01$ (5)	$2.8 \pm 0.3$ (5)	$1.05 \pm 0.03$ (5)	$0.62 \pm 0.05$ (6)	$1.01 \pm 0.03$ (6)
Atropine	$0.7 \pm 0.1$ (10)	$1.6 \pm 0.1$ (7)	$1.00 \pm 0.02$ (7)	$0.32 \pm 0.02$ (4)	$1.00 \pm 0.003$ (4)	$0.89 \pm 0.06$ (3)	$1.05 \pm 0.06$ (3)	$0.85 \pm 0.05$ (9)	$0.95 \pm 0.01$ (9)

Data on urinary bladder muscarinic receptors were derived from functional in vitro studies ( $K_B$ ) on carbachol-induced contractions of bladder strips and from competition binding studies ( $K_i$ ) in bladder homogenates, respectively.  $K_i$  values were derived from competition binding experiments with [ $^3$ H](–)-1-quinuclidinyl benzilate, as described in Section 2. Abbreviation:  $n_H$ , Hill coefficient. Results are mean  $\pm$  S.E.M. Numbers in parentheses indicate the number of experiments. Data for atropine from Nilvebrant and Sparf (1983a, 1986).




Fig. 3. Effect of tolterodine on the concentration-response curve to carbachol in human isolated urinary bladder. The contractile responses elicited by increasing concentrations of carbachol (cumulative additions) were recorded in the absence (control) and presence, respectively, of tolterodine at concentrations of 10 nM ( $\blacklozenge$ ), 30 nM ( $\blacktriangledown$ ) and 100 nM ( $\blacktriangle$ ). The time of incubation with tolterodine was 20 min. Control data ( $\bullet$ ) represent the mean ( $\pm$  S.E.M.) of 21 individual experiments. The  $EC_{50}$  value for carbachol was  $1.7 \pm 0.2 \mu\text{M}$ .

Tolterodine acted as a potent and competitive muscarinic receptor antagonist also in human isolated urinary bladder (Fig. 3). The Schild slope was 1.04 and  $pA_2$  8.4. The affinity of tolterodine, expressed as the  $K_B$ , was  $4.0 \pm 0.5 \text{ nM}$  ( $n = 16$ ). In addition, tolterodine effectively reduced the contractile response of human detrusor strips induced by electrical stimulation ( $IC_{50}$  64 nM) (Fig. 4).

### 3.1.2. Radioligand binding studies in tissue homogenates

The receptor-specific binding of [ $^3\text{H}$ ](–)-1-quinclidinyl benzilate in homogenates of human bladder, guinea-pig bladder (Fig. 5a), parotid gland (Fig. 5b), heart and cerebral cortex was effectively displaced by tolterodine. The dissociation constants ( $K_i$ ) were in the nanomo-




Fig. 4. Effect of tolterodine on electrically induced contraction (frequency 20–25 Hz, stimulus duration 0.8 ms, train duration 5 s, supramaximal voltage, stimulation interval of 2 min) of isolated preparations of human detrusor muscle ( $n = 6$ ) from one individual. The  $IC_{50}$  value was determined to be 64 nM.

lar range and the Hill slopes were close to unity in all tissues (Table 1). The affinities determined for tolterodine ( $K_i$   $3.3 \pm 0.4 \text{ nM}$ ;  $n = 6$ ) and oxybutynin ( $K_i$   $4.5 \pm 0.7 \text{ nM}$ ;  $n = 6$ ) in human bladder were comparable to those in the guinea-pig bladder (Table 1). The  $K_i$  value for tolterodine (3.3 nM) in the human bladder was similar to the  $K_B$  value (4.0 nM) derived from the functional studies. This correlation between radioligand binding and functional data was also shown for both tolterodine and oxybutynin in guinea-pig bladder, whereas atropine was slightly less potent in binding than in functional studies (Table 1).

The binding affinities determined in the bladder were similar to those in the heart, which can be assumed to contain only muscarinic  $M_2$  receptors. Tolterodine was roughly equipotent to oxybutynin and atropine in the




Fig. 5. Concentration-inhibition curves for tolterodine ( $\bullet$ ) and oxybutynin ( $\blacktriangledown$ ) in homogenates of guinea-pig urinary bladder (a) and parotid gland (b). Data represent mean ( $\pm$  S.E.M.) of 5–6 individual experiments. The inhibition curves, corrected for the radioligand-induced parallel shift as described in Section 2, represent the theoretical curves expected for an interaction with a single homogeneous population of binding sites. Binding parameters are shown in Table 1.






Fig. 6. Affinity profiles of tolterodine (a), oxybutynin (b) and atropine (c) at human m1–m5 muscarinic receptors expressed in Chinese hamster ovary cells. Binding studies were carried out under conditions of equilibrium, as described in Section 2.  $K_i$  values are shown in Table 2.




Fig. 7. Effect of tolterodine (a), oxybutynin (b) and atropine (c) on acetylcholine-induced urinary bladder contractions (■) and electrically induced salivation (◆) in the anaesthetised cat. The drugs were administered by intravenous infusion. Data are mean ( $\pm$ S.E.M.) of 5 animals.  $ID_{30}$  (threshold dose) and  $ID_{50}$  values are shown in Table 3.

Table 2  
Affinities, expressed as the dissociation constants ( $K_i$ ), for human muscarinic m1–m5 receptors expressed in Chinese hamster ovary cells

Compound	Parameter	Muscarinic receptor subtype				
		m1	m2	m3	m4	m5
Tolterodine	$K_i$ (nM)	3.0 ± 0.2	3.8 ± 0.7	3.4 ± 0.8	5.0 ± 0.8	3.4 ± 0.8
	$n_H$	1.03 ± 0.04	1.00 ± 0.04	1.06 ± 0.03	1.05 ± 0.07	1.00 ± 0.05
Oxybutynin	$K_i$ (nM)	2.4 ± 0.2	6.7 ± 0.9	0.67 ± 0.05	2.0 ± 0.5	11 ± 1.5
	$n_H$	1.03 ± 0.03	0.95 ± 0.03	1.06 ± 0.02	1.00 ± 0.03	1.04 ± 0.03
Atropine	$K_i$ (nM)	1.9 ± 0.2	2.9 ± 0.2	1.0 ± 0.1	1.0 ± 0.02	2.6 ± 0.3
	$n_H$	1.01 ± 0.04	0.95 ± 0.05	0.90 ± 0.03	1.01 ± 0.05	0.99 ± 0.03

$K_i$  values were derived from competition binding experiments with [ $^3$ H](–)-1-quinuclidinyl benzilate, as described in Section 2. Abbreviation:  $n_H$ , Hill coefficient. Results are expressed as mean ± S.E.M. of 5–6 separate experiments.

guinea-pig bladder (Fig. 5a), heart and cerebral cortex (Table 1). However, in the parotid gland ( $M_3$ ), tolterodine exhibited 8-times lower affinity than oxybutynin (Fig. 5b) and it was 6-times less potent than atropine (Table 1).

### 3.1.3. Radioligand binding studies in CHO cells

Tolterodine, oxybutynin and atropine were potent inhibitors of [ $^3$ H](–)-1-quinuclidinyl benzilate binding in homogenates of CHO cells expressing human muscarinic m1–m5 receptors (Table 2). In contrast to tolterodine, oxybutynin showed a distinct affinity profile, exhibiting the highest affinity for muscarinic m3 receptors and the lowest affinity for muscarinic m2 and m5 receptors (Fig. 6). The affinity of atropine at muscarinic m3 receptors was 2.9-times higher than at muscarinic m2 receptors. Oxybutynin, however, showed a 10-fold selectivity for muscarinic m3 over m2 (Table 2 and Fig. 6). In agreement with the data on cortical and cardiac homogenates, the affinity of tolterodine for muscarinic m1 and m2 receptors differed by less than a factor of two from those of oxybutynin and atropine. At muscarinic m3 receptors, oxybutynin was 5-times and atropine 3.4-times more potent than tolterodine.

### 3.2. In vivo studies

Intravenous infusion of tolterodine (21–2103 nmol/kg) in anaesthetised cats resulted in dose-dependent inhibition

of acetylcholine-induced urinary bladder contractions and electrically induced salivation. However, the effect on urinary bladder contractions occurred at significantly lower doses than the effect on salivary secretion (Fig. 7), showing that tolterodine exhibited favourable tissue selectivity with respect to these two responses. Thus, the threshold dose ( $ID_{30}$ ) for inhibition of bladder contractions was 40 nmol/kg, while 132 nmol/kg was required to produce a corresponding effect on salivary secretion (Table 3 and Fig. 7). This selectivity persisted at higher dose levels, i.e., when the bladder response was blocked by 75%, salivation was only inhibited by approximately 50% (Fig. 7). Tolterodine (21–631 nmol/kg) did not affect basal heart rate, while a slight decrease (< 10%) was observed after the highest dose (2103 nmol/kg).

In contrast to tolterodine, oxybutynin was significantly more potent in inhibiting salivary secretion than urinary bladder contractions (Table 3 and Fig. 7). Thus, salivation was blocked by 80% at the dose required for 50% inhibition of the urinary bladder response. At lower doses ( $\leq ID_{30}$ ), urinary bladder contractions and salivary secretion were affected to a similar degree. Atropine showed no selectivity in this in vivo model (Table 3 and Fig. 7). Neither oxybutynin nor atropine showed any effect on heart rate. Infusion of saline to control animals ( $n = 10$ , five infusions per experiment) caused little or no effect per se.

## 4. Discussion

Tolterodine is a new muscarinic receptor antagonist intended for the treatment of urinary urge incontinence and other symptoms of an overactive bladder. The aim of the present study was to compare the antimuscarinic properties of tolterodine with those of oxybutynin, the antimuscarinic drug most widely used in the treatment of urge incontinence (Wein et al., 1994; Yarker et al., 1995). The results of the in vitro studies showed that tolterodine is a potent and competitive antagonist at muscarinic receptors in urinary bladder preparations from guinea pigs and humans. Tolterodine was equipotent to oxybutynin, as shown by both functional and radioligand binding data in the guinea-pig bladder.

Table 3  
Inhibitory effects of tolterodine, oxybutynin and atropine on acetylcholine-induced urinary bladder contractions and electrically induced salivary secretion in the anaesthetised cat

Compound	$ID_{30}$ (nmol/kg)		$ID_{50}$ (nmol/kg)	
	Urinary bladder	Salivation	Urinary bladder	Salivation
Tolterodine	40 ± 8 <sup>a</sup>	132 ± 29	101 ± 8 <sup>a</sup>	257 ± 44
Oxybutynin	83 ± 13	50 ± 7	200 ± 23 <sup>b</sup>	104 ± 12
Atropine	9 ± 3	12 ± 2	18 ± 4	21 ± 4

The antagonists were administered by intravenous infusion.  $ID_{30}$  (threshold dose) and  $ID_{50}$  values were graphically determined. For purposes of comparison all data are given as nmol/kg. Results are mean ± S.E.M. of 5 separate experiments. <sup>a</sup>  $P < 0.05$  vs. effect on salivation, <sup>b</sup>  $P < 0.01$  vs. effect on salivation.

The potent antimuscarinic actions of tolterodine and oxybutynin on the bladder were confirmed *in vivo* in the anaesthetised cat. However, the most interesting finding was that tolterodine was significantly more potent in inhibiting urinary bladder contraction than salivation. Oxybutynin showed the reverse selectivity profile, while atropine was non-selective. Bladder contractions were induced by *i.a.* administration of acetylcholine and salivary secretion was induced by endogenous acetylcholine, released from the chorda-lingual nerve by electrical stimulation (Darke and Smaje, 1972). It may be argued that it would have been preferable to induce both responses using the same type of stimulation, *i.e.*, either electrically or chemically with a muscarinic agonist given intravenously. However, both of these methods have practical limitations. Thus, bladder contractions induced by electrical stimulation of the pelvic nerve are resistant to blockade by atropine and other muscarinic receptor antagonists, *i.e.*, the cholinergic component constitutes only about 30% of the response (unpublished observations), while the remainder is non-cholinergic non-adrenergic (NANC) mediated. This is well known to be the case in animal bladders, as shown in numerous *in vitro* and *in vivo* studies (Andersson, 1988, 1993; Wein et al., 1994). However, since it is generally accepted that bladder contractions in humans are mediated mainly by muscarinic receptors (Andersson, 1993; Wein et al., 1994), we found it more relevant to study only the cholinergic component of the bladder response in the cat. To avoid degradation of acetylcholine, it must be administered close to the target organ. Thus, we used *i.a.* injections because it is not possible to simultaneously stimulate both the bladder and the salivary glands by *i.v.* administration of acetylcholine without using doses high enough to kill the animals. We also tried to give stable analogues of acetylcholine (*e.g.*, carbachol, methacholine) by *i.v.* injection. In general, however, this method resulted in an unstable baseline for the bladder response over time, together with a low and variable salivary secretion. The inhibition exerted by muscarinic antagonists could therefore not be reliably determined and reproduced between animals (data not shown).

In our hands, stimulation of the bladder with *i.a.* acetylcholine and stimulation of the salivary gland by electrical means turned out to be the methods of choice, in terms of reliable and consistent responses. Both responses were elicited by the natural transmitter, acetylcholine, but the concentration of acetylcholine at the muscarinic receptors in the bladder and salivary gland is obviously unknown, as always in *in vivo* experiments. Thus, it cannot be excluded that a difference in end-organ activation to some extent can explain the bladder selectivity of tolterodine. However, in this context, it should be noted that the corresponding *in vivo* data on the two reference compounds, atropine and oxybutynin, were clearly in line with the general clinical experience with these drugs (Andersson, 1988; Wein et al., 1994; Yarker et al., 1995).

The selectivity profiles *in vivo* were reflected in the radioligand binding studies. Thus, the affinity profile of tolterodine (cerebral cortex  $\geq$  heart  $\approx$  urinary bladder  $>$  parotid gland) differed from those of oxybutynin (cerebral cortex  $\approx$  parotid gland  $>$  heart  $\approx$  urinary bladder) and atropine (cerebral cortex  $\geq$  parotid gland  $\approx$  heart  $\approx$  urinary bladder). In the cerebral cortex, heart and bladder, the three drugs were more or less equipotent. However, in the parotid gland, tolterodine was 6- and 8-times less potent, respectively, than atropine and oxybutynin. The guinea-pig urinary bladder contains a mixed population of muscarinic  $M_2/m_2$  and  $M_3/m_3$  receptors (Wang et al., 1995). The binding data on the bladder seemed to reflect the pharmacology of the muscarinic  $M_2$  receptors, since oxybutynin exhibited a similar affinity in bladder ( $K_i$  4.0 nM) and heart ( $M_2$ :  $K_i$  2.8 nM). The  $K_i$  values and the selectivity for cortical ( $K_i$  0.41 nM) and glandular ( $M_3$ :  $K_i$  0.62 nM) muscarinic receptors found for oxybutynin are in agreement with previous reports (Nilvebrant and Sparf, 1982, 1983b, 1986; Lazareno et al., 1990).

The selectivity of oxybutynin for muscarinic  $M_3$  over  $M_2$  receptors was confirmed in radioligand binding studies on CHO cells expressing the human muscarinic receptor subtypes. Thus, while tolterodine was non-selective, oxybutynin showed a 10-fold selectivity for muscarinic  $m_3$  over  $m_2$  receptors (Table 2 and Fig. 6). The same rank order of potency was found in the cell lines containing muscarinic  $m_1$ – $m_3$  receptors as in the tissue homogenates, *i.e.*, cerebral cortex and muscarinic  $m_1$  receptors: atropine  $\approx$  oxybutynin  $\approx$  tolterodine; heart and muscarinic  $m_2$  receptors: atropine  $\approx$  tolterodine  $\geq$  oxybutynin; parotid gland and muscarinic  $m_3$  receptors: oxybutynin  $\approx$  atropine  $>$  tolterodine. The only consistent difference between the drugs was found at the muscarinic  $m_3$  receptors, where tolterodine ( $K_i$  3.4 nM) was less potent than either oxybutynin ( $K_i$  0.67 nM) or atropine ( $K_i$  1.0 nM). Thus, tolterodine showed the same affinity at muscarinic  $m_2$  and  $m_3$  receptors ( $K_i$   $m_2/K_i$   $m_3$ : 1.1), while both oxybutynin ( $K_i$   $m_2/K_i$   $m_3$ : 9.6) and atropine ( $K_i$   $m_2/K_i$   $m_3$ : 2.9) had higher affinity at the muscarinic  $m_3$  receptors.

The selectivity of oxybutynin for muscarinic  $M_3/m_3$  over  $M_2/m_2$  receptors may indicate that the reverse tissue selectivity demonstrated for tolterodine and oxybutynin *in vivo* can be explained by their different affinities for muscarinic  $M_3/m_3$  receptors (Fig. 6). This explanation is, however, not in line with the current concept that contraction of most smooth muscles, including the bladder, is mediated only by the muscarinic  $M_3/m_3$  receptors (Hulme et al., 1990; Caulfield, 1993; Eglén et al., 1994; Wang et al., 1995; Tobin and Sjögren, 1995). On the other hand, according to this concept, tolterodine would have been expected to be less potent than oxybutynin in inhibiting contraction of isolated urinary bladder, since the affinity of oxybutynin for muscarinic  $M_3/m_3$  receptors was 5–8-times higher than that exhibited by tolterodine. However, the two compounds were equipotent in functional studies

on guinea-pig bladder and there was no disparity between functional ( $K_B$ ) and binding ( $K_i$ ) data, neither for oxybutynin ( $K_B$  4.4 nM;  $K_i$  4.0 nM) nor for tolterodine ( $K_B$  3.0 nM;  $K_i$  2.7 nM). The  $K_B$  value for tolterodine was similar to  $K_i$  values determined for both the  $M_2/m_2$  (1.6 and 3.8 nM, respectively) and muscarinic  $M_3/m_3$  receptors (4.8 and 3.4 nM, respectively), which is consistent with the lack of selectivity for either of these subtypes. The affinity of oxybutynin derived from functional studies ( $K_B$  4.4 nM), however, correlated better with its binding affinity at  $M_2/m_2$  ( $K_i$  2.8 and 6.7 nM, respectively) than at muscarinic  $M_3/m_3$  receptors ( $K_i$  0.62 and 0.67 nM, respectively). Thus, oxybutynin was 6–7-times less potent in inhibiting bladder contractions than in binding to muscarinic  $M_3/m_3$  receptors. Similar observations have been made with dicyclomine, i.e., the functional  $K_B$  value (24 nM) in the bladder is identical to the affinity for muscarinic  $M_2$  receptors (24 nM) in the heart, but not to that determined for muscarinic  $M_3$  receptors (2.8 nM) in the parotid gland (unpublished observations).

The tissue selectivity demonstrated for tolterodine *in vivo* cannot obviously be attributed to selectivity for a single muscarinic receptor subtype. However, the data on oxybutynin and atropine may indicate either that the muscarinic  $M_3/m_3$  receptors in glands are more sensitive to blockade than those in the urinary bladder, or that the muscarinic  $M_3/m_3$  receptors are heterogeneous (Eglen and Watson, 1996). An alternative explanation may be that also the muscarinic  $M_2/m_2$  receptors are involved in bladder contraction. The function of the large population of muscarinic  $M_2/m_2$  receptors present in most smooth muscles remains to be delineated, but it is clear that they mediate contraction under certain circumstances. Thus, muscarinic  $M_2$  receptors mediate contraction of the uterus, which contains no muscarinic  $M_3$  receptors (Eglen et al., 1989; Doods et al., 1993). In rat and guinea-pig ileum, stimulation of muscarinic  $M_2$  receptors results in contraction when the muscarinic  $M_3$  receptors have been selectively inactivated by alkylation (Thomas et al., 1993; Reddy et al., 1995). This has been interpreted as an indirect contraction caused by functional inhibition of  $\beta$ -adrenoceptor-mediated relaxation, since activation of muscarinic  $M_2$  receptors counteracts the accumulation of cAMP induced by  $\beta$ -adrenoceptor stimulation (Griffin and Ehlert, 1992; Thomas et al., 1993; Eglen et al., 1994; Reddy et al., 1995). Similarly, it has been suggested that activation of muscarinic  $M_2$  receptors in canine colon circular muscle directly enhances the effect of muscarinic  $M_3$  receptor stimulation by preventing relaxation via inhibition of cAMP production (Zhang and Buxton, 1991). It is thus possible, as pointed out by Eglen et al. (1994), that both muscarinic  $M_2$  and  $M_3$  receptors modulate smooth muscle contraction and that the balance between the relaxant and contractile state is dependent on the prevailing parasympathetic or sympathetic drive. This is interesting with respect to urinary bladder function, since urine stor-

age in some species is facilitated by sympathetic reflexes that mediate an inhibition of bladder activity during the filling phase (De Groat et al., 1993; Khadra et al., 1995). Carbachol inhibits adenylyl cyclase activity and both carbachol and acetylcholine stimulate the production of inositol phosphates in human detrusor (Andersson, 1993). Thus, in analogy with intestinal smooth muscles, activation of the muscarinic  $M_2$  receptors in the bladder may contribute to the micturition contraction by counteracting the sympathetic relaxation.

Another candidate role for muscarinic  $M_2/m_2$  receptors in smooth muscle contraction has been indicated by Caulfield (1993), who suggested that low concentrations of agonist activate the muscarinic  $M_2/m_2$  receptors to evoke contraction via an inward current, causing depolarisation and opening of voltage-gated calcium channels, while higher concentrations of the agonist activate muscarinic  $M_3/m_3$  receptors to elicit contraction via an increase in  $IP_3$  and intracellular calcium. Similarly, both muscarinic  $M_2$  and  $M_3$  receptors seem to be involved in the contractile response of the gall bladder. The muscarinic  $M_2$  receptors appear to be linked to calcium influx, while the muscarinic  $M_3$  receptors are preferentially associated with intracellular calcium release (Chen et al., 1995).

Muscarinic receptors involved in the regulation of transmitter release are present on both adrenergic and cholinergic nerves in the detrusor of different species (Andersson, 1993). The inhibitory muscarinic receptors on adrenergic neurones remain to be subclassified. However, postganglionic cholinergic nerves in the rat bladder (Somogyi and De Groat, 1992; Somogyi et al., 1994) and cholinergic nerves in rabbit detrusor (Tobin and Sjögren, 1995) exhibit a mixed population of inhibitory muscarinic  $M_2$  and facilitatory muscarinic  $M_1$  receptors. Facilitatory prejunctional muscarinic  $M_1$  receptors have also been demonstrated in the human detrusor (Flood et al., 1994), and it has been suggested that they may serve as an amplification mechanism during micturition (Somogyi and De Groat, 1992; Somogyi et al., 1994; Flood et al., 1994). In guinea-pig bladder, the inhibitory muscarinic receptors on cholinergic nerves are reported to be of the muscarinic  $M_4$  subtype (Alberts, 1995). Thus, the regulation of bladder function is complex and the relative importance of the different muscarinic receptor subtypes *in vivo*, under normal and various pathological conditions, is still unknown.

In conclusion, tolterodine was shown to be a potent and competitive antagonist at bladder muscarinic receptors. The results on tolterodine and oxybutynin showed that it is possible to separate the antimuscarinic effects on the bladder and salivary glands *in vivo*. The *in vitro* data indicated that the reverse selectivity patterns observed for tolterodine and oxybutynin may be related to the difference in relative affinity for muscarinic  $M_3/m_3$  and  $M_2/m_2$  receptors, and that the muscarinic  $M_2/m_2$  receptors may contribute to bladder contraction. The muscarinic receptor function in smooth muscles is obviously more complex than previ-

ously believed (Caulfield, 1993; Eglen et al., 1994) and, with respect to the urinary bladder, the relative functional importance of the postjunctional muscarinic  $M_2/m_2$  and  $M_3/m_3$  receptors and the prejunctional inhibitory ( $M_2/M_4$ ) and facilitatory ( $M_1$ ) receptors remains to be clarified, particularly in vivo.

### Acknowledgements

We would like to thank Prof. Lars Norlén and Dr Gunnar Tobin for their generous help with the in vivo model. The technical assistance of Britt Arvidsson, Gunnel Fredrickson, Gunilla Glas, Johan Löthberg, Ali-Reza Modiri, Lise-Lotte Ohlsson, Staffan Sundquist, Kristina Winroth and Birgitta Öhman (Department of Pharmacology, Pharmacia & Upjohn AB, Uppsala, Sweden) and Lisa Jansson, Brita Sundén-Andersson and Berit Holmskov (Department of Clinical Pharmacology, University Hospital, Lund, Sweden) is gratefully acknowledged. This study was supported in part by the Swedish Medical Research Council (No. 6837).

### References

- Alberts, P., 1995. Classification of the presynaptic muscarinic receptor subtype that regulates  $^3H$ -acetylcholine secretion in the guinea pig urinary bladder in vitro. *J. Pharmacol. Exp. Ther.* 274, 458–468.
- Andersson, K.-E., 1988. Current concepts in the treatment of disorders of micturition. *Drugs* 35, 477–494.
- Andersson, K.-E., 1993. The pharmacology of lower urinary tract smooth muscles and penile erectile tissues. *Pharmacol. Rev.* 45, 253–308.
- Bradford, M.M., 1976. A rapid and sensitive method for the quantification of microgram quantities of protein using the principle of protein-dye binding. *Anal. Biochem.* 72, 248–254.
- Buckley, N.J., Bonner, T.I., Buckley, C.M., Brann, M.R., 1989. Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells. *Mol. Pharmacol.* 35, 469–476.
- Caulfield, M.P., 1993. Muscarinic receptor – characterization, coupling and function. *Pharmacol. Ther.* 58, 319–379.
- Chen, Q., Yu, P., De Petris, G., Biancani, P., Behar, J., 1995. Distinct muscarinic receptors and signal transduction pathways in gallbladder muscle. *J. Pharmacol. Exp. Ther.* 273, 650–655.
- Darke, A.C., Smaje, L.H., 1972. Dependence of functional vasodilatation in the cat submaxillary gland upon stimulation frequency. *J. Physiol.* 226, 191–203.
- De Groat, W.C., Booth, A.M., Yoshimura, N., 1993. Neurophysiology of micturition and its modification in animal models of human disease. In: Maggi, C.A. (Ed.), *Nervous Control of the Urogenital System*. Harwood Academic Publishers, Amsterdam, pp. 227–290.
- Doods, H.N., Willim, K.D., Boddeke, H.W.G.M., Entzeroth, M., 1993. Characterization of muscarinic receptors in guinea pig uterus. *Eur. J. Pharmacol.* 250, 223–230.
- Eglen, R.M., Watson, N., 1996. Selective muscarinic receptor agonists and antagonists. *Pharmacol. Toxicol.* 78, 59–68.
- Eglen, R.M., Michel, A.D., Whiting, R.L., 1989. Characterization of the muscarinic receptor subtype mediating contraction of the guinea pig uterus. *Br. J. Pharmacol.* 96, 497–499.
- Eglen, R.M., Reddy, H., Watson, N., Challis, R.A.J., 1994. Muscarinic acetylcholine receptors in smooth muscle. *Trends Pharmacol. Sci.* 15, 114–119.
- Flood, H.D., Somogyi, G.T., Bellinger, M.F., Groat, W.C., 1994. Muscarinic facilitation of acetylcholine release in the human bladder: a mechanism for enhancement of micturition contractions. In: *Proceedings of the 24th Annual Meeting of the International Continence Society*; Aug. 31–Sept. 2, 1994, Prague. p. 62.
- Giraldo, E., Vigano, M.A., Hammer, R., Ladinsky, H., 1987. Characterization of muscarinic receptors in guinea pig ileum longitudinal smooth muscle. *Mol. Pharmacol.* 33, 617–625.
- Griffin, M.T., Ehlert, F.J., 1992. Specific inhibition of isoproterenol-stimulated cyclic AMP accumulation by  $M_2$  muscarinic receptors in rat intestinal smooth muscle. *J. Pharmacol. Exp. Ther.* 263, 221–225.
- Hulme, E.C., Birdsall, N.J.M., Buckley, N.J., 1990. Muscarinic receptor subtypes. *Annu. Rev. Pharmacol. Toxicol.* 30, 633–673.
- Jacobs, S., Chang, K.-J., Cuatrecasas, P., 1975. Estimation of hormone receptor affinity by competitive displacement of labelled ligand. *Biochem. Biophys. Res. Commun.* 66, 687–692.
- Khadra, M.H., Satchell, P.M., Vaughan, C.W., 1995. Sympathetic nervous system effects on feline bladder wall compliance throughout continence. *Acta Physiol. Scand.* 155, 31–39.
- Kondo, S., Morita, T., Tashima, Y., 1995. Muscarinic cholinergic receptor subtypes in human detrusor muscle studied by labeled and non-labeled pirenzepine, AFDX-116 and 4DAMP. *Urol. Int.* 54, 150–153.
- Lazareno, S., Buckley, N.J., Roberts, F.F., 1990. Characterization of muscarinic  $M_4$  binding sites in rabbit lung, chicken heart and NG108-15 cells. *Mol. Pharmacol.* 38, 805–815.
- Lowry, O.H., Rosebrough, N.J., Farr, A.L., Randall, R.J., 1951. Protein measurement with the Folin phenol reagent. *J. Biol. Chem.* 193, 265–275.
- Maeda, A., Kubo, T., Mishima, M., Numa, S., 1988. Tissue distribution of mRNAs encoding muscarinic acetylcholine receptor subtypes. *FEBS Lett.* 239, 339–342.
- Michel, A.D., Whiting, R.L., 1988. Methocitramine reveals heterogeneity of the  $M_2$  muscarinic receptors in longitudinal ileal smooth muscle membranes. *Eur. J. Pharmacol.* 145, 305–311.
- Nilvebrant, L., 1986. On the muscarinic receptors in the urinary bladder and the putative subclassification of muscarinic receptors. *Acta Pharmacol. Toxicol.* 59 (Suppl. 1), 1–45.
- Nilvebrant, L., Sparf, B., 1982. Muscarinic receptor binding in the guinea pig parotid gland. Different affinities of some anticholinergic drugs between the parotid gland and ileum. *Scand. J. Gastroenterol.* 17 (Suppl. 72), 69–77.
- Nilvebrant, L., Sparf, B., 1983a. Differences between binding affinities of some antimuscarinic drugs in the parotid gland and those in the urinary bladder and ileum. *Acta Pharmacol. Toxicol.* 53, 304–313.
- Nilvebrant, L., Sparf, B., 1983b. Muscarinic receptor binding in the guinea pig urinary bladder. *Acta Pharmacol. Toxicol.* 52, 30–38.
- Nilvebrant, L., Sparf, B., 1986. Dicyclomine, benzhexol and oxybutynin distinguish between subclasses of muscarinic binding sites. *Eur. J. Pharmacol.* 123, 133–143.
- Nilvebrant, L., Sparf, B., 1988. Receptor binding profiles of some selective muscarinic antagonists. *Eur. J. Pharmacol.* 151, 83–96.
- Nilvebrant, L., Andersson, K.-E., Mattiasson, A., 1985. Characterization of the muscarinic cholinceptors in the human detrusor. *J. Urol.* 134, 418–423.
- Noronha-Blob, L., Kachur, J.F., 1991. Enantiomers of oxybutynin: in vitro pharmacological characterization at  $M_1$ ,  $M_2$  and  $M_3$  receptors and in vivo effects on urinary bladder contraction, mydriasis and salivary secretion in guinea pigs. *J. Pharmacol. Exp. Ther.* 256, 562–567.
- Reddy, H., Watson, N., Ford, A.P.D.W., Eglen, R.M., 1995. Characterization of the interaction between muscarinic  $M_2$  receptors and  $\beta$ -adrenoceptor subtypes in guinea pig isolated ileum. *Br. J. Pharmacol.* 114, 49–56.
- Schild, H.I., 1949.  $pA_x$  and competitive drug antagonism. *Br. J. Pharmacol. Chemother.* 4, 277–280.
- Somogyi, G.T., De Groat, W.C., 1992. Evidence for inhibitory nicotinic

- and facilitatory muscarinic receptors in cholinergic nerve terminals of the rat urinary bladder. *J. Auton. Nerv. Syst.* 37, 89–98.
- Somogyi, G.T., Tanowitz, M., De Groat, W.C., 1994. M<sub>1</sub> muscarinic receptor-mediated facilitation of acetylcholine release in the rat urinary bladder. *J. Physiol.* 480, 81–89.
- Thomas, E.A., Baker, S.A., Ehlert, F.J., 1993. Functional role for the M<sub>2</sub> muscarinic receptor in smooth muscle of guinea pig ileum. *Mol. Pharmacol.* 44, 102–110.
- Wein, A.J., Longhurst, P.A., Levin, R.M., 1994. Pharmacologic treatment of voiding dysfunction. In: Munday, R.A., Stephenson, T.P., Wein, A.J. (Eds.), *Urodynamics: Principles, Practice and Application*, 2nd ed. Churchill Livingstone, New York, NY, pp. 43–70.
- Yamaguchi, O., Shishido, K., Tamura, K., Ogawa, T., Fujimura, T., 1994. Evaluation of mRNA encoding muscarinic receptor subtypes in human detrusor muscle. *Neurorol. Urodyn.* 13, 464–465.